156 related articles for article (PubMed ID: 29035381)
21. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
Newell P; Toffanin S; Villanueva A; Chiang DY; Minguez B; Cabellos L; Savic R; Hoshida Y; Lim KH; Melgar-Lesmes P; Yea S; Peix J; Deniz K; Fiel MI; Thung S; Alsinet C; Tovar V; Mazzaferro V; Bruix J; Roayaie S; Schwartz M; Friedman SL; Llovet JM
J Hepatol; 2009 Oct; 51(4):725-33. PubMed ID: 19665249
[TBL] [Abstract][Full Text] [Related]
22. The hsa_circRNA_102049 mediates the sorafenib sensitivity of hepatocellular carcinoma cells by regulating
Wang S; Liu D; Wei H; Hua Y; Shi G; Qiao J
Bioengineered; 2022 Feb; 13(2):2272-2284. PubMed ID: 35034536
[TBL] [Abstract][Full Text] [Related]
23. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1.
Xu J; Ji L; Liang Y; Wan Z; Zheng W; Song X; Gorshkov K; Sun Q; Lin H; Zheng X; Chen J; Jin RA; Liang X; Cai X
Signal Transduct Target Ther; 2020 Dec; 5(1):298. PubMed ID: 33361760
[TBL] [Abstract][Full Text] [Related]
24. Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.
Hu C; Li W; Tian F; Jiang K; Liu X; Cen J; He Q; Qiu Z; Kienast Y; Wang Z; Zhang H; Ji Y; Hu J; Hui L
J Hepatol; 2018 Mar; 68(3):465-475. PubMed ID: 29113912
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma.
Liu J; Cui X; Qu L; Hua L; Wu M; Shen Z; Lu C; Ni R
Exp Mol Pathol; 2016 Aug; 101(1):58-65. PubMed ID: 27302463
[TBL] [Abstract][Full Text] [Related]
26. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X
J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148
[TBL] [Abstract][Full Text] [Related]
27. PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy.
Zheng JF; He S; Zeng Z; Gu X; Cai L; Qi G
Mol Ther; 2019 Oct; 27(10):1784-1795. PubMed ID: 31337603
[TBL] [Abstract][Full Text] [Related]
28. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
[TBL] [Abstract][Full Text] [Related]
29. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.
Song Z; Liu T; Chen J; Ge C; Zhao F; Zhu M; Chen T; Cui Y; Tian H; Yao M; Li J; Li H
Cancer Lett; 2019 Sep; 460():96-107. PubMed ID: 31247273
[TBL] [Abstract][Full Text] [Related]
30. Transcriptional and posttranscriptional regulation of HOXA13 by lncRNA HOTTIP facilitates tumorigenesis and metastasis in esophageal squamous carcinoma cells.
Lin C; Wang Y; Wang Y; Zhang S; Yu L; Guo C; Xu H
Oncogene; 2017 Sep; 36(38):5392-5406. PubMed ID: 28534516
[TBL] [Abstract][Full Text] [Related]
31. LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells.
Sun J; Zheng X; Wang B; Cai Y; Zheng L; Hu L; Lu X; Xie S; Zhang X; Liu H; Ye L
Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(2):261-270. PubMed ID: 35130616
[TBL] [Abstract][Full Text] [Related]
32. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
[TBL] [Abstract][Full Text] [Related]
33. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic function of the homeobox A13-long noncoding RNA HOTTIP-insulin growth factor-binding protein 3 axis in human gastric cancer.
Wang SS; Wuputra K; Liu CJ; Lin YC; Chen YT; Chai CY; Lin CS; Kuo KK; Tsai MH; Wang SW; Chen KK; Miyoshi H; Nakamura Y; Saito S; Hanafusa T; Wu DC; Lin CS; Yokoyama KK
Oncotarget; 2016 Jun; 7(24):36049-36064. PubMed ID: 27144338
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.
Bai S; Nasser MW; Wang B; Hsu SH; Datta J; Kutay H; Yadav A; Nuovo G; Kumar P; Ghoshal K
J Biol Chem; 2009 Nov; 284(46):32015-27. PubMed ID: 19726678
[TBL] [Abstract][Full Text] [Related]
36. Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines.
Zhang Z; He CZ; Qin YQ; Liao JJ; Huang ST; Mo S; Li HM; Lin JY
Aging (Albany NY); 2020 Nov; 12(23):24255-24269. PubMed ID: 33234725
[TBL] [Abstract][Full Text] [Related]
37. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
38. RNA m
Lin Z; Niu Y; Wan A; Chen D; Liang H; Chen X; Sun L; Zhan S; Chen L; Cheng C; Zhang X; Bu X; He W; Wan G
EMBO J; 2020 Jun; 39(12):e103181. PubMed ID: 32368828
[TBL] [Abstract][Full Text] [Related]
39. HOTTIP and HOXA13 are oncogenes associated with gastric cancer progression.
Chang S; Liu J; Guo S; He S; Qiu G; Lu J; Wang J; Fan L; Zhao W; Che X
Oncol Rep; 2016 Jun; 35(6):3577-85. PubMed ID: 27108607
[TBL] [Abstract][Full Text] [Related]
40. RABL2A-CCDC34 Axis Promotes Sorafenib Resistance in Hepatocellular Carcinoma.
Zhou M; Chen X; Bai H; Sun Y; Zhang Z; Li S; Wang X; Zeng M
DNA Cell Biol; 2021 Nov; 40(11):1418-1427. PubMed ID: 34767735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
